Clozapine and cardiometabolic health in chronic schizophrenia: correlations and consequences in a clinical context

REFERENCES

• Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet 2005; 366: 1059–1062.
   PubMed Web of Science ®Google Scholar
• Dekker JM, Girman C, Rhodes T . Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666–673.
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415–1428.
   PubMed Web of Science ®Google Scholar
• Lakka H, Laaksonen D, Lakka T . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Journal of the American Medical Association 2002; 288: 2709–2716.
   PubMed Web of Science ®Google Scholar
• John AP, Koloth R, Dragovic M, Lim SC. Prevalence of metabolic syndrome among Australians with severe mental illness. Medical Journal of Australia 2009; 190: 176–179.
   PubMed Web of Science ®Google Scholar
• Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Australian & New Zealand Journal of Psychiatry 2007; 41: 606–610.
   PubMed Web of Science ®Google Scholar
• Cameron AJ, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE. The Metabolic Syndrome in Australia: Prevalence using four definitions. Diabetes Research and Clinical Practice 2007; 77: 471–478.
   Google Scholar
• Janus ED, Laatikainen T, Dunbar JA . Overweight, obesity and metabolic syndrome in rural southeastern Australia. Medical Journal of Australia 2007; 187: 147–152.
   PubMed Web of Science ®Google Scholar
• Zimmet P, Alberti K, Shaw J. Mainstreaming the metabolic syndrome: a definitive definition. Medical Journal of Australia 2005; 183: 175–176.
   PubMedGoogle Scholar
• Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. British Journal of Psychiatry 2000; 177: 212–217.
   PubMed Web of Science ®Google Scholar
• Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophrenia Research 2008; 98: 287–294.
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease [see comment]. American Heart Journal 2005; 150: 1115–1121.
   PubMed Web of Science ®Google Scholar
• Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophrenia Research 2000; 45: 21–28.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Hussain I, O’Brien SM, Dineen B, Griffin D, McDonald C. Prevalence and associations of the metabolic syndrome among patients prescribed clozapine. Irish Journal of Medical Science 2008; 177: 205–210.
   Google Scholar
• Suvisaari JM, Saarni SI, Perala J . Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. Journal of Clinical Psychiatry 2007; 68: 1045–1055.
   PubMed Web of Science ®Google Scholar
• Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. British Journal of Psychiatry 2007; 191: 23–29.
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 2007; 7: 14.
   PubMed Web of Science ®Google Scholar
• De Hert MA, van Winkel R, Van Eyck D . Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Research 2006; 83: 87–93.
   PubMed Web of Science ®Google Scholar
• Meyer J, Loh C, Leckband SG . Prevalence of the metabolic syndrome in veterans with schizophrenia. Journal of Psychiatric Practice 2006; 12: 5–10.
   PubMedGoogle Scholar
• Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. Journal of Clinical Psychiatry 2006; 67: 595–583.
   Google Scholar
• Hagg SAB, Lindblom YC, Mjorndal TA, Adolfsson RC. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. International Clinical Psychopharmacology 2006; 21: 93–98.
   PubMed Web of Science ®Google Scholar
• Lamberti JS, Olson D, Crilly JF . Prevalence of the metabolic syndrome among patients receiving clozapine. American Journal of Psychiatry 2006; 163: 1273–1276.
   PubMed Web of Science ®Google Scholar
• Saari KM, Lindeman SM, Viilo KM . A 4-fold risk of metabolic syndrome in patients with schizophrenia: The Northern Finland 1966 Birth Cohort Study. Journal of Clinical Psychiatry 2005; 66: 559–563.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC . Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 2005; 80: 19–32.
   PubMed Web of Science ®Google Scholar
• Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Canadian Journal of Psychiatry – Revue Canadienne de Psychiatrie 2004; 49: 753–760.
   PubMed Web of Science ®Google Scholar
• Malhi GS, Adams D, Plain JM. Metabolic syndrome: a picture of health? Acta Neurop-sychiatrica 2009, 21:197–199
   Google Scholar
• von Hausswolff-Juhlin Y, Bjartveit M, Lindstrom E, Jones P. Schizophrenia and physical health problems. Acta Psychiatrica Scandinavica, Supplementum 2009: 15–21.
   Google Scholar
• Waterreus AJ, Laugharne JD. Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Medical Journal of Australia 2009; 190: 185–189.
   PubMed Web of Science ®Google Scholar
• Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TMS. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Candian Journal of Psychiatry 2006; 51: 382–386.
   PubMed Web of Science ®Google Scholar
• Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabetic Medicine 2007; 24: 481–485.
   PubMed Web of Science ®Google Scholar
• van Nimwegen LJ, Storosum JG, Blumer RM . Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. Journal of Clinical Endocrinology & Metabolism 2008; 93: 572–577.
   Google Scholar
• Connolly M, Kelly C. Lifestyle and physical health in schizophrenia. Advances in Psychiatric Treatment 2005; 11: 125–132.
   Google Scholar
• Berk M. Should we be targeting smoking as a routine intervention? Acta Neuropsychiatrica 2007; 19: 131–132.
   Web of Science ®Google Scholar
• Moeller-Saxone K. Cigarette smoking and interest in quitting among consumers at a Psychiatric Disability Rehabilitation and Support Service in Victoria. Australian & New Zealand Journal of Public Health 2008; 32: 479–481.
   PubMed Web of Science ®Google Scholar
• Levander S, Eberhard J, Lindstrom E. Nicotine use and its correlates in patients with psychosis. Acta Psychiatrica Scandinavica, Supplementum 2007: 27–32.
   Google Scholar
• Berk M. Should we be targeting exercise as a routine mental health intervention? Acta Neuropsychiatrica 2007; 19: 217–218.
   Web of Science ®Google Scholar
• Malhi GS. Weight gain: gained by waiting? Acta Psychiatrica Scandinavica 2003; 108: 249–251.
   Google Scholar
• Malhi GS, Mitchell PB, Caterson I. ‘Why getting fat, Doc?’ Weight gain and psychotropic medications. Australian & New Zealand Journal of Psychiatry 2001; 35: 315–321.
   PubMed Web of Science ®Google Scholar
• Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harvard Review of Psychiatry 2006; 14: 152–164.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatrica Scandinavica 2009; 119: 171–179.
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M . Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999; 156: 1686–1696.
   PubMed Web of Science ®Google Scholar
• De Hert M, Schreurs V, Sweers K . Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophrenia Research 2008; 101: 295–303.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Nguyen DD, Copeland PM . Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. Journal of Clinical Psychiatry 2005; 66: 1116–1121.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Cagliero E, Gray C . Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. American Journal of Psychiatry 2000; 157: 975–981.
   PubMed Web of Science ®Google Scholar
• National Health and Medical Research Council. Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults. Canberra: Government of Australia, 2003.
   Google Scholar
• Royal Australian and New Zealand College of Psychiatrists. Australian and New Zealand College of Psychaitrists clinical practice guidelines for the treatment of schizoprhenia and related disorders. Australian and New Zealand Journal of Psychiatry 2005; 39: 1–30.
   Google Scholar
• National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in adults in Primary and Secondary Care. NICE Clinical Guideline 82. London: NHS, 2009.
   Google Scholar
• Buckley PF, Shendarkar N. Treatment-refractory schizophrenia. Current Opinion in Psychiatry 2005; 18: 165–173.
   Google Scholar
• Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research 2004; 70: 1–17.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatrica Scandinavica 2009; 119: 4–14.
   PubMed Web of Science ®Google Scholar
• Birkenaes AB, Birkeland KI, Engh JA . Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. Journal of Clinical Psychopharmacology 2008; 28: 132–137.
   PubMed Web of Science ®Google Scholar
• Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis [see comment]. Neuropsychopharmacology 2007; 32: 765–772.
   PubMed Web of Science ®Google Scholar
• Cameron AJ, Welborn TA, Zimmet PZ . Overweight and obesity in Australia: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Medical Journal of Australia 2003; 178: 427–432.
   PubMed Web of Science ®Google Scholar
• Goff DC, Sullivan LM, McEvoy JP . A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research 2005; 80: 45–53.
   PubMed Web of Science ®Google Scholar
• Walter G, DeLaroche A, Soh N . Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry 2008; 16: 253–262.
   PubMed Web of Science ®Google Scholar
• Nguyen D, Brakoulias V, Boyce P. An evaluation of monitoring practices in patients on second generation antipsychotics. Australasian Psychiatry 2009; 17: 295–299.
   PubMed Web of Science ®Google Scholar